Understanding how RPL3L ribosomes work in heart and muscle cells
Official title: Mechanisms and functions of RPL3L ribosomes
Funded at Columbia University Health Sciences · NIH-11020957 · Data updated 2026-11-12
This study is looking at a special protein called RPL3L in heart and muscle cells to see how it works differently from a more common protein, which could help us understand heart problems and muscle growth better, especially for those with serious heart conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | February 1, 2024 |
| Project end | January 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $497,206 |
| NIH project number | 5R01HL171664-02 |
| Project ID | NIH-11020957 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include adults with genetic mutations linked to cardiac diseases, particularly those experiencing severe heart failure or dilated cardiomyopathy.
✕Less likely to help
Patients with non-genetic heart conditions or those outside the age range of 21 years and older may not benefit from this research.
What this research studies
This research investigates the role of RPL3L, a specific ribosomal protein, in adult heart and muscle cells. It aims to understand how RPL3L ribosomes differ from the more common RPL3 ribosomes, particularly in their function and regulation during muscle growth and protein synthesis. The study will explore genetic mutations associated with severe heart conditions, providing insights into the mechanisms behind these diseases. By examining the expression and function of RPL3L, the research seeks to uncover important biological processes that could impact muscle health.
Why it matters
Potential benefit: If successful, this research could lead to new insights into heart and muscle diseases, potentially improving treatment options for patients with these conditions.
How similar studies have gone: While the specific focus on RPL3L is novel, previous research has shown success in understanding ribosomal protein functions in relation to muscle and heart diseases.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Wu, Xuebing — Columbia University Health Sciences
- Study coordinator: Wu, Xuebing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.